Skip to main content
Category

News Archive

National Foundation for Cancer Research Logo

2/28 Deadline to Apply for $ (oncology innovation)…

By News Archive

for The Rockville-based National Foundation for Cancer Research is accepting applications through Sunday evening, February 28, from academic laboratory and early stage start-up-based promising oncology technology projects for its 2021 Salisbury Award Competition for Entrepreneurial Translational Research. In addition to increased exposure, insight from a world-class judging panel and access to NFCR’s network, cash prizes totaling $10,000 will be provided to three category winners, the first one of which who will also be introduced to the AIM-HI Accelerator Fund for consideration of investment.  Learn more and apply here: https://www.nfcr.org/salisbury-award/.

National Foundation for Cancer Research Logo

Salisbury Award for Entrepreneurial Translational Research – NFCR

By News Archive

National Foundation for Cancer Research Logo

The National Foundation for Cancer Research is proud to present the Salisbury Award in honor of the Salisbury family’s vision and legacy of funding “high risk, high impact, and high reward” cancer research. Over 80 years of service, the three Salisburys galvanized NFCR into a significant force in cancer research worldwide.

The Salisbury Award encourages and promotes innovative scientists and early stage startups to translate their discoveries into therapies that can improve the lives of cancer patients. The initiative is designed to catalyze and advance promising research innovations onto the path of commercialization. Download the flyer and help spread the word!

 

Read More
Cursor and Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA Engineered Cell Therapy for Frontline Cancer Cartesian

Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer – Cartesian

By News Archive

Cursor and Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA Engineered Cell Therapy for Frontline Cancer Cartesian

Gaithersburg, MD, Feb. 22, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering mRNA-engineered cell therapy in and beyond oncology, today announced that it has initiated a Phase 2a clinical trial of its mRNA chimeric antigen receptor (CAR) T-cell therapy, Descartes-11, in patients with newly diagnosed, high-risk multiple myeloma.  Based upon the company’s research and analysis, this program is understood to be the first RNA-engineered cell therapy to enter clinical development for a frontline cancer. Descartes-11 is the third product candidate to be evaluated in clinical trials resulting from Cartesian’s RNA Armory℠ engineering platform.

 

Read More

Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico | Novavax Inc. – IR Site

By News Archive

Novavax Logo

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of the company’s COVID-19 vaccine. Novavax has previously reported positive interim efficacy results of NVX-CoV2373, its recombinant protein-based vaccine candidate, in an ongoing Phase 3 clinical trial taking place in the United Kingdom.

 

Read More
eyedea Medical Logo

Eyedea Medical Joins Baltimore’s LaunchPort™ Medtech Venture Center

By News Archive

eyedea Medical Logo

The LaunchPort™ announced today that Eyedea Medical (https://www.eyedeamedical.com/) joined the Venture Center and will make the Port Covington, Baltimore location their HQ and engineering site.

Eyedea Medical is an early-stage, ophthalmic medical device company that was spun out of the Wilmer Eye Institute and the Center for Bioengineering Innovation & Design at Johns Hopkins University. Eyedea Medical was formed by a group of ophthalmologists and biomedical engineers in 2019 to alleviate the burden of corneal blindness globally through development and commercialization of a series of devices with potential to improve outcomes and access to vision-restoring corneal procedures.

 

Read More

Maryland Today | Pandemic Fighter’s Priorities

By News Archive

Dr. Kathleen Neuzil '83, director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine, designs and oversees U.S. vaccine trials. An avid athlete and Maryland sports fan, she played softball as a UMD undergrad (below) and recently tailgated on campus with her husband and three children (bottom).
(Portrait courtesy of University of Maryland, Baltimore; softball and family photos courtesy of Dr. Kathleen Neuzil ’83)

One of the nation’s leading scientists in the desperate campaign to develop coronavirus vaccines—and in the Hollywood-esque triumph of succeeding within a year—grew up just across the street from the University of Maryland. Underlying all that work is her hope of returning to campus.

“I’m fighting the pandemic partly so I can get back to my Terps season tickets,” said Dr. Kathleen Neuzil ’83, lamenting a men’s basketball season played in a mostly empty Xfinity Center.

Image: Dr. Kathleen Neuzil ’83, director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine, designs and oversees U.S. vaccine trials. An avid athlete and Maryland sports fan, she played softball as a UMD undergrad (below) and recently tailgated on campus with her husband and three children (bottom). (Portrait courtesy of University of Maryland, Baltimore; softball and family photos courtesy of Dr. Kathleen Neuzil ’83)

Read More
novavax logo

Novavax Expands COVID-19 Collaboration and License Agreement with SK Bioscience | BioPharm International

By News Archive

novavax logo

On Feb. 15, 2021, biotechnology company Novavax and SK Bioscience, a vaccine business subsidiary of SK Group, announced an expanded collaboration and license agreement for SK Bioscience to add significant production capacity for Novavax’s COVID-19 vaccine, currently in Phase III clinical trials.

This new agreement follows an already existing manufacturing arrangement under which SK Bioscience obtained a license to manufacture and commercialize NVX-CoV2373, Novavax’s COVID-19 vaccine, for sale to the Korean government. Novavax recently reported positive interim efficacy results for the vaccine candidate in an ongoing Phase III clinical trial in the United Kingdom and is also currently conducting a Phase III trial in the United States and Mexico.

 

Read More
NewImage

Internship pipeline helps close the equity gap during pandemic | Hub

By News Archive

NewImage

Lubna Azmi sees herself as a laidback person, but even she isn’t immune to the pressures and anxieties that come with planning for the future.

“I’ve seen how fast people’s professional lives can fall apart, especially during the pandemic,” says Azmi, who is a second-year international studies and sociology major at Johns Hopkins. “During quarantine, I was asking myself, have I been too selfish thinking about doing what I want to do? Should I be thinking about how to better support my family, including the family I create in the future?”

Image: Alia Poonawala (left), executive director of Hire Hopkins, and Alayna Hayes, senior director of life design for diversity, equity, and inclusion – https://hub.jhu.edu

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.